Literature DB >> 12414778

Defibrination of blood plasma for use in serological tests for syphilis.

Arnold R Castro1, Susan E Kikkert, Martha B Fears, Victoria Pope.   

Abstract

Syphilitic plasma can be salvaged from discarded blood donations and converted to serum by defibrination. Sixty-nine units of plasma were treated with a stock solution of 100 U of thrombin per ml in 1 M calcium chloride and then with a 10% (wt/vol) solution of kaolin. Fibrinogen concentrations detected in initial plasma samples ranged from 94 to 4970 mg/liter (mean, 2532 mg/liter) for samples that were reactive by the rapid plasma reagin circle card test (RPR) and from 314 to 2742 mg/liter (mean 1528 mg/liter) for samples that were not reactive by the RPR. The treated samples showed no measurable fibrinogen remaining after the defibrination process. In the nontreponemal RPR for syphilis, 86% of the treated plasma samples retained the same endpoint titer as that of the initial plasma sample. When the Treponema pallidum passive-particle-agglutination test was used, 98% retained the same reactivity. In the Captia Syphilis-G enzyme immunoassay, 89% of the treated samples demonstrated no change in reactivity index, and in the fluorescent treponemal antibody absorption test, 96% showed no reduction in fluorescence. Human sera containing antibodies to syphilis are used at the Centers for Disease Control and Prevention for the preparation of reference controls or as samples for proficiency testing. Finding reactive sera is becoming more difficult due to the general decline of syphilis cases in the United States. The decreasing availability of these sera can be alleviated by salvaging plasma and converting it to serum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414778      PMCID: PMC130115          DOI: 10.1128/cdli.9.6.1376-1378.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  3 in total

1.  Elimination of syphilis in the United States.

Authors:  M E St Louis; J N Wasserheit
Journal:  Science       Date:  1998-07-17       Impact factor: 47.728

2.  [Defibrination of blood plasma for obtaining hemagglutinating sera].

Authors:  V A Potkin-Posadskiĭ
Journal:  Probl Gematol Pereliv Krovi       Date:  1970-07

3.  The necessity for heating sera for the VDRL slide test.

Authors:  M A Lantz; V H Falcone
Journal:  Am J Med Technol       Date:  1968-10
  3 in total
  5 in total

Review 1.  The Laboratory Diagnosis of Syphilis.

Authors:  Ferris Satyaputra; Stephanie Hendry; Maxwell Braddick; Pirathaban Sivabalan; Robert Norton
Journal:  J Clin Microbiol       Date:  2021-05-12       Impact factor: 5.948

2.  A comparison of the analytical level of agreement of nine treponemal assays for syphilis and possible implications for screening algorithms.

Authors:  Heather Jost; Arnold Castro; David Cox; Yetunde Fakile; Susan Kikkert; Ye Tun; Akbar Zaidi; Mahin Park
Journal:  BMJ Open       Date:  2013-09-19       Impact factor: 2.692

3.  Evaluation of the WHO/CDC Syphilis Serology Proficiency Programme to support the global elimination of mother-to-child transmission of syphilis: an observational cross-sectional study, 2008-2015.

Authors:  André O Hopkins; Thuy Trinh; Yetunde F Fakile; Allan Pillay; Melanie M Taylor; Ellen Kersh; Mary Kamb
Journal:  BMJ Open       Date:  2020-01-09       Impact factor: 2.692

4.  Chelonid Alphaherpesvirus 5 Prevalence and First Confirmed Case of Sea Turtle Fibropapillomatosis in Grenada, West Indies.

Authors:  Amanda James; Annie Page-Karjian; Kate E Charles; Jonnel Edwards; Christopher R Gregory; Sonia Cheetham; Brian P Buter; David P Marancik
Journal:  Animals (Basel)       Date:  2021-05-21       Impact factor: 2.752

5.  Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study.

Authors:  Patrick J Horner; Gillian S Wills; Antoinette Righarts; Sueli Vieira; Daphne Kounali; Dhanraj Samuel; Alan Winston; David Muir; Nigel P Dickson; Myra O McClure
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.